鼠神经生长因子联合银杏叶提取物治疗糖尿病视神经病变疗效观察

Clinical observation on treating diabetic optic neuropathy with mNGF plus EGB

目的:探讨研究鼠神经生长因子(苏肽生)肌内注射联合银杏叶提取物注射液治疗糖尿病视神经病变的机制及疗效。方法:将糖尿病视神经病变患者242眼随机分为鼠神经生长因子组(A组)58眼,银杏叶提取物注射液治疗组(B组)58眼,神经生长因子联合银杏叶提取物注射液组(C组)62眼以及对照组(D组)64眼。对照组采用常规治疗(控制血糖、视网膜光凝治疗)。A组在常规治疗方案上,使用鼠神经生长因子肌肉注射,B组使用银杏叶提取物注射液静滴治疗,C组使用鼠神经生长因子和银杏叶提取物注射液联合应用,连续21d为一个疗程。通过观察FFA、VEPF等指标对各组疗效进行比较。结果:A、B、C组有效率分别为82.8%、86.2%、96.8%,对照组总有效率为71.8%,差异均有统计学意义(P均<0.05)。结论:鼠神经生长因子联合银杏叶提取物治疗糖尿病视神经病变疗效好,早期应用效果更明显。

Objective To evaluate clinical efficacy of mouse nerve growth factor plus extract of ginkgo biloba on diabetic opticneuropathy. Methods： 242 patients were randomly divided into 4 groups. 58 eyes in the group A were treated with mNGF; 58 eyes inthe group B were treated with EGB; 62 eyes in the group C were treated with mNGF plus EGB; 64 eyes in the group D were treated byconventional treatment such as control blood glucose, retinal photocoagulation. In 21 days, clinical efficacy in groups was determined byFFA and VEPF and so on. Results： The effective rates in the group A, the group B and the group C were 82.8%, 86.2%, 96.8% respectively.The effective rate in the group D was 71.8%, with statistically significant difference （P〈0.05）. Conclusion： The clinical efficiency of mNGFplus EGB on diabetic optic neuropathy was significant, and obvious clinical efficacy should gain at early stage.